Tiagabine: efficacy and safety in partial seizures – current status

Tiagabine: efficacy and safety in partial seizures – current status

Jürgen Bauer, Déirdre Cooper-MahkornDepartment of Epileptology, Bonn University Hospital, GermanyAbstract: Tiagabine hydrochloride (TGB) is a selective gamma-aminobutyric acid (GABA) reuptake inhibitor. TGB is effective as an add-on medication in adults and children 12 ye...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jürgen Bauer, Déirdre Cooper-Mahkorn
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2008
Materias:
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Acceso en línea:https://doaj.org/article/5cfbeb7d45bc4e028fe12bcd568d236a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:5cfbeb7d45bc4e028fe12bcd568d236a
record_format dspace
spelling oai:doaj.org-article:5cfbeb7d45bc4e028fe12bcd568d236a2021-12-02T04:32:59ZTiagabine: efficacy and safety in partial seizures – current status1176-63281178-2021https://doaj.org/article/5cfbeb7d45bc4e028fe12bcd568d236a2008-09-01T00:00:00Zhttp://www.dovepress.com/tiagabine-efficacy-and-safety-in-partial-seizures-ndash-current-status-a2198https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Jürgen Bauer, Déirdre Cooper-MahkornDepartment of Epileptology, Bonn University Hospital, GermanyAbstract: Tiagabine hydrochloride (TGB) is a selective gamma-aminobutyric acid (GABA) reuptake inhibitor. TGB is effective as an add-on medication in adults and children 12 years and older in the treatment of partial seizures. Results of nonrandomized add-on trials with TGB show treatment success with seizure reduction of at least 50% in 33% to 46% of patients. In newly diagnosed patients with partial epilepsy, TGB monotherapy was as effective as carbamazepine. Comedication with TGB elevates the risk of nonconvulsive status (7.8% vs 2.7% without TGB). The most common side effects include dizziness/lightheadedness, asthenia/lack of energy and somnolence. TGB has no negative effects on cognition; it does not increase the risk of fractures or rash. TGB may interfere with color perception. TGB presents an intermediate risk for depression in patients with epilepsy (approximately 4%). Regarding the risk of overdose, 96–680 mg TGB (mean 224 mg) caused seizures or coma. TGB is an antiepileptic drug exhibiting a specific anticonvulsive mechanism of action, the efficacy of which is relatively low when used in comedication. Critical side effects, such as the induction of nonconvulsive status epilepticus, further limit its use.Keywords: epilepsy, tiagabine, antiepileptic drugs, status epilepticus, pharmacotherapy Jürgen BauerDéirdre Cooper-MahkornDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2008, Iss Issue 4, Pp 731-736 (2008)
institution DOAJ
collection DOAJ
language EN
topic Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Jürgen Bauer
Déirdre Cooper-Mahkorn
Tiagabine: efficacy and safety in partial seizures – current status
description Jürgen Bauer, Déirdre Cooper-MahkornDepartment of Epileptology, Bonn University Hospital, GermanyAbstract: Tiagabine hydrochloride (TGB) is a selective gamma-aminobutyric acid (GABA) reuptake inhibitor. TGB is effective as an add-on medication in adults and children 12 years and older in the treatment of partial seizures. Results of nonrandomized add-on trials with TGB show treatment success with seizure reduction of at least 50% in 33% to 46% of patients. In newly diagnosed patients with partial epilepsy, TGB monotherapy was as effective as carbamazepine. Comedication with TGB elevates the risk of nonconvulsive status (7.8% vs 2.7% without TGB). The most common side effects include dizziness/lightheadedness, asthenia/lack of energy and somnolence. TGB has no negative effects on cognition; it does not increase the risk of fractures or rash. TGB may interfere with color perception. TGB presents an intermediate risk for depression in patients with epilepsy (approximately 4%). Regarding the risk of overdose, 96–680 mg TGB (mean 224 mg) caused seizures or coma. TGB is an antiepileptic drug exhibiting a specific anticonvulsive mechanism of action, the efficacy of which is relatively low when used in comedication. Critical side effects, such as the induction of nonconvulsive status epilepticus, further limit its use.Keywords: epilepsy, tiagabine, antiepileptic drugs, status epilepticus, pharmacotherapy
format article
author Jürgen Bauer
Déirdre Cooper-Mahkorn
author_facet Jürgen Bauer
Déirdre Cooper-Mahkorn
author_sort Jürgen Bauer
title Tiagabine: efficacy and safety in partial seizures – current status
title_short Tiagabine: efficacy and safety in partial seizures – current status
title_full Tiagabine: efficacy and safety in partial seizures – current status
title_fullStr Tiagabine: efficacy and safety in partial seizures – current status
title_full_unstemmed Tiagabine: efficacy and safety in partial seizures – current status
title_sort tiagabine: efficacy and safety in partial seizures – current status
publisher Dove Medical Press
publishDate 2008
url https://doaj.org/article/5cfbeb7d45bc4e028fe12bcd568d236a
work_keys_str_mv AT jampuumlrgenbauer tiagabineefficacyandsafetyinpartialseizuresampndashcurrentstatus
AT dampeacuteirdrecoopermahkorn tiagabineefficacyandsafetyinpartialseizuresampndashcurrentstatus
_version_ 1718401186110898176

Ejemplares similares